Jump Financial LLC Has $25.58 Million Stock Position in Moderna, Inc. $MRNA

Key Points

• Jump Financial LLC significantly increased its ownership in Moderna, acquiring 886,567 shares and scaling up its position by 5,590%, holding approximately 902,427 shares valued at $25.58 million.
• Moderna's stock price saw a rise of 3.4%, with its latest opening price at $27.12 and a market cap of $10.55 billion.
• Institutional investors collectively own 75.33% of Moderna's shares, reflecting strong interest from the investment community despite recent earnings showing a revenue decline of 41.1% year-over-year.

Jump Financial LLC raised its holdings in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 5,590.0% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 902,427 shares of the company's stock after acquiring an additional 886,567 shares during the period. Jump Financial LLC owned approximately 0.23% of Moderna worth $25,584,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of MRNA. S Bank Fund Management Ltd acquired a new stake in shares of Moderna in the first quarter valued at $25,000. SVB Wealth LLC acquired a new stake in shares of Moderna in the first quarter valued at $28,000. Costello Asset Management INC acquired a new stake in shares of Moderna in the first quarter valued at $30,000. Sentry Investment Management LLC acquired a new stake in shares of Moderna in the first quarter valued at $31,000. Finally, Deseret Mutual Benefit Administrators lifted its holdings in shares of Moderna by 53.3% in the first quarter. Deseret Mutual Benefit Administrators now owns 1,128 shares of the company's stock valued at $32,000 after buying an additional 392 shares during the period. Institutional investors and hedge funds own 75.33% of the company's stock.

Wall Street Analysts Forecast Growth

MRNA has been the subject of several research analyst reports. Cowen initiated coverage on Moderna in a report on Sunday, July 13th. They issued a "hold" rating for the company. Wells Fargo & Company restated an "equal weight" rating on shares of Moderna in a report on Sunday, July 13th. Morgan Stanley restated an "equal weight" rating and issued a $32.00 price objective on shares of Moderna in a report on Friday, August 1st. Royal Bank Of Canada cut their price objective on Moderna from $32.00 to $28.00 and set a "sector perform" rating for the company in a report on Friday, May 2nd. Finally, Citigroup assumed coverage on Moderna in a report on Friday, August 1st. They set a "neutral" rating and a $40.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, sixteen have assigned a Hold rating and four have given a Sell rating to the stock. According to data from MarketBeat, Moderna currently has an average rating of "Hold" and a consensus target price of $42.88.

Moderna Stock Performance

NASDAQ:MRNA traded up $0.37 during trading hours on Wednesday, hitting $25.10. 18,645,369 shares of the company's stock traded hands, compared to its average volume of 10,746,746. The firm has a market cap of $9.77 billion, a P/E ratio of -3.33 and a beta of 1.83. Moderna, Inc. has a twelve month low of $23.15 and a twelve month high of $80.56. The stock's fifty day moving average price is $29.15 and its two-hundred day moving average price is $28.97.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its quarterly earnings results on Friday, August 1st. The company reported ($2.13) earnings per share for the quarter, beating the consensus estimate of ($2.99) by $0.86. The firm had revenue of $142.00 million for the quarter, compared to analyst estimates of $116.26 million. Moderna had a negative return on equity of 25.96% and a negative net margin of 94.31%.Moderna's quarterly revenue was down 41.1% on a year-over-year basis. During the same period in the previous year, the firm earned ($3.33) earnings per share. Moderna has set its FY 2025 guidance at EPS. On average, equities research analysts predict that Moderna, Inc. will post -9.61 earnings per share for the current year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.